InterMune, Inc.

Company ahead of schedule in phase III clinical trial of Actimmune

Published in Pharma Investments, Ventures and Law Weekly, December 18th, 2005

InterMune, Inc. (ITMN) announced that it has enrolled the 600th patient in its pivotal phase III INSPIRE clinical trial almost 2 months ahead of schedule. The randomized, double-blind, placebo-controlled INSPIRE trial, is designed to determine if Actimmune (interferon gamma-1b) decreases mortality in patients with idiopathic pulmonary fibrosis (IPF).

The trial is scheduled to conclude approximately 2 years after the 600th patient enrolls, or around the end of 2007.

Last month, InterMune announced its decision, based on pre-specified criteria in the study protocol, to enroll an additional 200 patients in the trial to increase the likelihood of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2005-12-18)

More Articles from Pharma Investments, Ventures and Law Weekly

A.P. Pharma, Inc.
Developer of polymer-based drug delivery systems evaluating financing options
Aastrom Biosciences, Inc
Stem cell therapy developer reports net loss of $0.03 per share
Aceto Corp.
Chemically derived drug maker reports $5.4M decline in sales
Acusphere, Inc.
Microparticle drug developer reports on operational progress
Advanced BioPhotonics, Inc.
Medical imaging developer obtains $4M financing
Advanced Magnetics, Inc.
Nanotechnology company reports loss of $0.36 per share
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry